Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA7 | P43166 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 10/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90687 | 1.00 | CA1 (0.63) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL89892 | 1.00 | CA1 (0.63) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL15081305 | 0.89 | CA1 (0.53) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL3370592 | 0.86 | CA1 (0.67) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL7420759 | 0.86 | CA1 (0.67) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL2216700 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL2216702 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL1429655 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL19041565 | 0.83 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL12396265 | 0.83 | CA1 (0.67) | CA1CA2CA7CYP2D6CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-09-12 | — | — | US | disclosed |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113166143-B | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods | 舒万诺知识产权公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210323962-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-10-21 | — | — | US | disclosed |
| CN-113166143-A | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods | 3M创新有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IRF3, IFNAR1, IFNG | CA1 2015/4885CA2 757/4885CA7 1118/4885 |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | IFNG, IFNAR1, IRF3 | CA1 3992/4885CA2 4002/4885CA7 3374/4885 |
| US-20210323962-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, IRF3 | CA1 4661/4885CA2 4408/4885CA7 4044/4885 |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, IRF3 | CA1 4661/4885CA2 4408/4885CA7 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.